Rebamipide prevents occurrence of gastric lesions following transcatheter arterial embolization in the hepatic artery

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 5, 1999, Pages 495-499

  Nomura, Hideyuki ^a   Miyake, Katsuhisa ^a   Hirakata, Ryosuke ^a   Migita, Shinobu ^a   Okamoto, Osamu ^a   Shiraishi, Genji ^a  

^a Shin Kokura Hospital   (Japan)

Author keywords

Gastric lesion; Rebamipide; Transcatheter arterial embolization

Indexed keywords

DOXORUBICIN; IODINATED POPPYSEED OIL; REBAMIPIDE;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGIONAL PERFUSION; STOMACH MUCOSA LESION; STOMACH PROTECTION;

EID: 0032989676     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01889.x     Document Type: Article

References (27)

1. 1 Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolism. Radiology 1993; 188: 79-83.
2. 2 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
3. 3 Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology 1988; 94: 453-6.
4. 4 Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: An analysis by Cox proportional hazard model. Cancer 1991; 68: 2150-4.
5. 5 Lau GKK, Hui WM, Hu S, Ngan H, Lam SK. Occurrence of acute gastroduodenitis after transcatheter-oily-chemoembolization (TOCE): Role of gastroduodenal microcirculation (Abstract). Gastroenterology 1996; 110: A1246.
6. 6 Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 141-5.
7. 7 Genecin P, Groszmann RJ. Portal hypertension. In: Schiff L, Schiff ER, eds. Diseases of the Liver. Philadelphia: JB Lippincott Co., 1993; 935-73.
8. 8 Marshall BJ, Warren JR, Francis GJ et al. Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am. J. Gastroenterol. 1987; 82: 200-10.
9. 9 Seldinger SI. Catheter replacement of the needle in percutaneous arteriography. Acta Radiol. 1952; 39: 368-76.
10. 10 Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N. Engl. J. Med. 1980; 303: 136-8.
11. 11 McAlindon ME, Muller AF, Filipowicz B, Hawkey CJ. Effect of allopurinol, sulphasalazine and vitamin C on aspirin induced gastroduodenal injury in human volunteers. Gut 1996; 38: 518-24.
12. 12 Murray FE, Hudson N, Atherton JC, Cole AT, Scheck F, Hawkey CJ. Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut 1996; 38: 11-14.
13. 13 Stachura J, Konturek JW, Denbinski A, Domschke W. Do infiltrating leukocytes contribute to the adaptation of human gastric mucosa to continued aspirin administration? Scand. J. Gastroenterol. 1994; 29: 966-72.
14. 14 Konturek JW, Denbinski A, Stoll R, Konturek M, Domschke W. Gastric mucosal blood flow and neutrophil activation in aspirin-induced gastric mucosal damage in man. Scand. J. Gastroenterol. 1993; 28: 767-71.
15. 15 McCormack TT, Sims J, Eyre-Brook I et al. Gastric lesions in portal hypertension: Inflammatory gastritis or congestive gastropathy. Gut 1985; 26: 1226-32.
16. 16 Vigneri S, Termini R, Piraino A, Scialabba A, Pisciotta G, Fontana N. The stomach in liver cirrhosis. Endoscopic, morphological and clinical correlations. Gastroenterology 1991; 101: 472-8.
17. 2 in gastric mucosa of patients with alcoholic cirrhosis and portal hypertension. Gastroenterology 1987; 93: 135-40.
18. 18 Sato T, Imamura M, Sasaki I, Ohneda A. Gastric acid secretion and gastrin and gastric inhibitory polypeptide release in cirrhotic patients. Am. J. Gastroenterol. 1985; 80: 163-9.
19. 19 Tytgat GNJ. The Sydney system: Endoscopic division. Endoscopic appearances in gastritis/duodenitis. J. Gastroenterol. Hepatol. 1991; 6: 223-34.
20. 20 Papazian A, Braillon A, Dupas JL, Sevenet F, Capron JP. Portal hypertensive gastric mucosa: An endoscopic study. Gut 1986; 27: 1199-203.
21. 21 Yamasaki K, Kanbe T, Yabuuchi Y. Inhibition of PAF-induced gastric mucosal lesion in the rat by pramipide (OPC-12759), a novel antiulcer agent: Involvement of oxygen-derived tree radicals. Gastroenterology 1989; 96: A556.
22. 22 Okabe S, Hiramatsu Y, Yamasaki K, Sakurai I, Shima T. Effect of rebamipide on HCI-taurocholate-induced gastritis in rats. Ther. Res. 1991; 12: 3253-63.
23. 23 Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur. J. Pharmacol. 1987; 142: 23-9.
24. 24 Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig. Dis. Sci. 1993; 38: 1441-9.
25. 25 Naito Y, Yoshikawa T, Matsuyama K et al. Effect of rebamipide, a novel anti-ulcer agent, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Pathophysiology 1994; 1: 161-4.
26. 26 Ogino K, Hobara T, Ishiyama H et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcer in rats. Eur. J. Pharmacol. 1992; 212: 9-13.
27. 27 Itou M, Guth PH. Role of oxygen derived free radicals in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology 1985; 88: 1162-7.